Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
2.130
+0.070 (3.40%)
At close: Jun 26, 2026, 4:00 PM EDT
2.130
0.00 (-0.01%)
After-hours: Jun 26, 2026, 7:54 PM EDT
Allogene Therapeutics Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for Allogene Therapeutics stock have an average target of 8.65, with a low estimate of 3.85 and a high estimate of 14. The average target predicts an increase of 306.10% from the current stock price of 2.13.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Allogene Therapeutics stock from 13 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 10 | 10 | 10 | 9 | 8 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 2 | 2 | 2 |
| Sell | 1 | 1 | 1 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 15 | 15 | 15 | 14 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $10 | Buy | Maintains | $10 | +369.48% | May 29, 2026 |
| William Blair | William Blair | Buy Maintains n/a | Buy | Maintains | n/a | n/a | May 14, 2026 |
| Oppenheimer | Oppenheimer | Buy Reiterates $7 | Buy | Reiterates | $7 | +228.64% | May 14, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $9 | Buy | Maintains | $9 | +322.54% | May 14, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $14 | Buy | Maintains | $14 | +557.28% | May 14, 2026 |
Financial Forecast
Revenue This Year
6.00K
Revenue Next Year
12.97M
from 6.00K
Increased by 216,118.50%
EPS This Year
-0.61
from -0.85
EPS Next Year
-0.68
from -0.61
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 60,000 | 63.5M | |
| Avg | 6,000 | 13.0M | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2027 | 2028 |
|---|---|---|
| High | 1,058,233.3% | 2,227.9% |
| Avg | 216,118.5% | 647.9% |
| Low | -100.0% | -100.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.58 | -0.42 | |
| Avg | -0.61 | -0.68 | |
| Low | -0.66 | -1.00 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.